RecruitingNCT07399002

LONG NAGOMI™ PMCF STUDY

Long Coronary Lesions: Safety and Performance of the Ultimaster Nagomi™ Stent in This Setting With a One-to-one Approach -One Lesion, One Stent- LONG NAGOMI™ PMCF STUDY

Sponsor

Fundación EPIC

Enrollment

1,039 participants

Start Date

Feb 27, 2026

Study Type

OBSERVATIONAL

Conditions

Coronary Artery Disease Ischemic Heart Disease

Summary

The study is designed as a prospective, multi-center, observational PMCF (post-market clinical follow-up) study of the Ultimaster Nagomi™ \_stent (lengths of 38, 44 and 50 mm) in the treatment of coronary artery disease according to the indications approved in the CE marking.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called LONG NAGOMI for people with coronary artery disease and ischemic heart disease. The study is currently recruiting participants at 7 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICELONG NAGOMI

Patients in whom treatment with long nagomi has been attempted

Locations(7)

Hospital Universitario de Cabueñes

Cabueñes, Spain

Hospital General Universitario de Elche

Elche, Spain

Hospital Universitario Juan Ramón Jiménez

Huelva, Spain

Hospital Universitario de Leon

León, Spain

Hospital Universitario Regional de Málaga

Málaga, Spain

Hospital Universitario de Navarra

Pamplona, Spain

Hospital Universitario Marqués de Valdecilla

Santander, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07399002

Related Trials

Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions

NCT0719069018 locations

Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

NCT0677963023 locations